Perrigo Company, a leading supplier of consumer health products announces today that the US Food and Drug Administration has given final clearance for omeprazole magnesium delayed mini capsules, 20mg OTC. Perrigo is planning to make Omeprazole Minis available in the latter part of this year.
AstraZeneca announced to sell omeprazole and its associated brand's global commercial rights to Cheplapharm Arzneimittel GmbH.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 2477
Published Date: Sep 05, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing cases of gastroesophageal reflux, increasing awareness among people, and increasing prevalence of duodenal ulcers.
The market size of omeprazole is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Boehringer Ingelheim, AstraZeneca Plc., Azurity Pharma, Perrigo Company Plc, Salix Pharmaceuticals, Mochida Pharmaceutical Co., Ltd., Yoshindo Inc, Fuji Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Takeda Pharmaceuticals Co., Ltd and others.
The capsule segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.